135 related articles for article (PubMed ID: 36070882)
1. Arsenic trioxide and Erlotinib loaded in RGD-modified nanoliposomes for targeted combination delivery to PC3 and PANC-1 cell lines.
Khosravani F; Mir H; Mirzaei A; Kobarfard F; Bardania H; Hosseini E
Biotechnol Appl Biochem; 2023 Apr; 70(2):811-823. PubMed ID: 36070882
[TBL] [Abstract][Full Text] [Related]
2. RGD-decorated nanoliposomes for combined delivery of arsenic trioxide and curcumin to prostate cancer cells.
Khosravani F; Amiri F; Mahmoudi R; Morshedi D; Kobarfard F; Alipour M; Hosseini E; Bardania H
Naunyn Schmiedebergs Arch Pharmacol; 2024 Apr; 397(4):2347-2357. PubMed ID: 37831114
[TBL] [Abstract][Full Text] [Related]
3. A novel RGDyC/PEG co-modified PAMAM dendrimer-loaded arsenic trioxide of glioma targeting delivery system.
Lu Y; Han S; Zheng H; Ma R; Ping Y; Zou J; Tang H; Zhang Y; Xu X; Li F
Int J Nanomedicine; 2018; 13():5937-5952. PubMed ID: 30323584
[TBL] [Abstract][Full Text] [Related]
4. Targeting of EGFR increase anti-cancer effects of arsenic trioxide: Promising treatment for glioblastoma multiform.
Mesbahi Y; Zekri A; Ahmadian S; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Eur J Pharmacol; 2018 Feb; 820():274-285. PubMed ID: 29274334
[TBL] [Abstract][Full Text] [Related]
5. RGD conjugated liposome-hollow silica hybrid nanovehicles for targeted and controlled delivery of arsenic trioxide against hepatic carcinoma.
Fei W; Zhang Y; Han S; Tao J; Zheng H; Wei Y; Zhu J; Li F; Wang X
Int J Pharm; 2017 Mar; 519(1-2):250-262. PubMed ID: 28109899
[TBL] [Abstract][Full Text] [Related]
6. Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair.
Kryeziu K; Jungwirth U; Hoda MA; Ferk F; Knasmüller S; Karnthaler-Benbakka C; Kowol CR; Berger W; Heffeter P
Mol Cancer Ther; 2013 Jun; 12(6):1073-84. PubMed ID: 23548265
[TBL] [Abstract][Full Text] [Related]
7. Combination effects of arsenic trioxide and fibroblast growth factor receptor inhibitor in squamous cell lung carcinoma.
Lam SK; Leung LL; Li YY; Zheng CY; Ho JC
Lung Cancer; 2016 Nov; 101():111-119. PubMed ID: 27794399
[TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide-induced cytotoxicity in A549 cells: The role of necroptosis.
Jamil M; Mohammadi-Bardbori A; Safa O; Nikpoor AR; Bakhtari A; Mokhtarinejad M; Zadeh SN; Shadboorestan A; Omidi M
Drug Res (Stuttg); 2023 Sep; 73(7):417-425. PubMed ID: 37230480
[TBL] [Abstract][Full Text] [Related]
9. Basic mechanisms of arsenic trioxide (ATO)-induced apoptosis in human leukemia (HL-60) cells.
Yedjou C; Tchounwou P; Jenkins J; McMurray R
J Hematol Oncol; 2010 Aug; 3():28. PubMed ID: 20796291
[TBL] [Abstract][Full Text] [Related]
10. Polymeric micelles for GSH-triggered delivery of arsenic species to cancer cells.
Zhang Q; Vakili MR; Li XF; Lavasanifar A; Le XC
Biomaterials; 2014 Aug; 35(25):7088-100. PubMed ID: 24840615
[TBL] [Abstract][Full Text] [Related]
11. Combinatorial Effect of Arsenic and Herbal Compounds in Telomerase-Mediated Apoptosis Induction in Liver Cancer.
Chaudhary A; Bhardwaj SK; Khan A; Srivastava A; Sinha KK; Ali M; Haque R
Biol Trace Elem Res; 2023 Jul; 201(7):3300-3310. PubMed ID: 36192614
[TBL] [Abstract][Full Text] [Related]
12. Bcl-2 hijacks the arsenic trioxide resistance in SH-SY5Y cells.
Wang J; Peng X; Yang D; Guo M; Xu X; Yin F; Wang Y; Huang J; Zhan L; Qi Z
J Cell Mol Med; 2022 Jan; 26(2):563-569. PubMed ID: 34910369
[TBL] [Abstract][Full Text] [Related]
13. Arsenic trioxide preferentially induces nonapoptotic cell deaths as well as actin cytoskeleton rearrangement in the CHO AA8 cell line.
Izdebska M; Klimaszewska-Wiśniewska A; Lewandowski D; Marcin Nowak J; Gagat M; Grzanka A
Postepy Hig Med Dosw (Online); 2014 Dec; 68():1492-500. PubMed ID: 25531713
[TBL] [Abstract][Full Text] [Related]
14. A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells.
Wang W; Adachi M; Zhang R; Zhou J; Zhu D
Pancreas; 2009 May; 38(4):e114-23. PubMed ID: 19342982
[TBL] [Abstract][Full Text] [Related]
15. Cryptotanshinone enhances the effect of Arsenic trioxide in treating liver cancer cell by inducing apoptosis through downregulating phosphorylated- STAT3 in vitro and in vivo.
Shen L; Zhang G; Lou Z; Xu G; Zhang G
BMC Complement Altern Med; 2017 Feb; 17(1):106. PubMed ID: 28187727
[TBL] [Abstract][Full Text] [Related]
16. Combined arsenic trioxide-cisplatin treatment enhances apoptosis in oral squamous cell carcinoma cells.
Nakaoka T; Ota A; Ono T; Karnan S; Konishi H; Furuhashi A; Ohmura Y; Yamada Y; Hosokawa Y; Kazaoka Y
Cell Oncol (Dordr); 2014 Apr; 37(2):119-29. PubMed ID: 24599717
[TBL] [Abstract][Full Text] [Related]
17. Galectin-3 inhibition sensitizes human renal cell carcinoma cells to arsenic trioxide treatment.
Xu Y; Gu X; Gong M; Guo G; Han K; An R
Cancer Biol Ther; 2013 Oct; 14(10):897-906. PubMed ID: 23917726
[TBL] [Abstract][Full Text] [Related]
18. Ethacrynic acid and a derivative enhance apoptosis in arsenic trioxide-treated myeloid leukemia and lymphoma cells: the role of glutathione S-transferase p1-1.
Wang R; Liu C; Xia L; Zhao G; Gabrilove J; Waxman S; Jing Y
Clin Cancer Res; 2012 Dec; 18(24):6690-701. PubMed ID: 23082001
[TBL] [Abstract][Full Text] [Related]
19. Novel combination therapy of prostate cancer cells with arsenic trioxide and flutamide: An in-vitro study.
Mirzaei A; Akbari MR; Tamehri Zadeh SS; Khatami F; Mashhadi R; Aghamir SMK
Tissue Cell; 2022 Feb; 74():101684. PubMed ID: 34800879
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of thymidylate synthase and E2F1 by arsenic trioxide in mesothelioma.
Lam SK; Li YY; Zheng CY; Ho JC
Int J Oncol; 2015 Jan; 46(1):113-22. PubMed ID: 25335113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
